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Abstract 
Objective: To assemble expected values for free-living steps/day in special populations living 
with chronic illnesses and disabilities. Method: Studies identified since 2000 were categorized 
into similar illnesses and disabilities, capturing the original reference, sample descriptions, 
descriptions of instruments used (i.e., pedometers, piezoelectric pedometers, accelerometers), 
number of days worn, and mean and standard deviation of steps/day. Results: Sixty unique 
studies represented: 1) heart and vascular diseases, 2) chronic obstructive lung disease, 3) 
diabetes and dialysis, 4) breast cancer, 5) neuromuscular diseases, 6) arthritis, joint replacement, 
and fibromyalgia , 7) disability (including mental retardation/intellectual difficulties), and 8) 
other special populations. A median steps/day was calculated for each category. Waist-mounted 
and ankle-mounted instruments were considered separately due to fundamental differences in 
assessment properties. For waist-mounted instruments, the lowest median values for steps/day 
are found in disabled older adults (1,214 steps/day) followed by people living with COPD (2,237 
steps/day). The highest values were seen in individuals with Type 1 diabetes (8,008 steps/day), 
mental retardation/intellectual disability (7,787 steps/day), and HIV (7, 545 steps/day). 
Conclusion: This review will be useful to researchers/practitioners who work with individuals 
living with chronic illness and disability and require such information for surveillance, screening, 
intervention, and program evaluation purposes.  
Keywords: exercise, walking, ambulatory monitoring 
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Introduction 
The benefits of a physically active lifestyle particularly relevant to special populations 
living with chronic illness and disability, however, we know little about the actual physical 
activity patterns of such special populations (Tudor-Locke and Myers, 2001). Accurate 
quantification of physical activity behaviors using feasible and appropriate assessment tools is 
essential to epidemiologists, physiologists, and behavioral scientists, as well as clinicians 
charged with the treatment of chronic illness and disability.  
Objective monitoring of physical activity, using body worn accelerometers and 
pedometers, has advanced greatly in recent years. Accelerometers contain a piezoelectric 
element and typically provide time-stamped estimates of activity volume (i.e., total counts or 
steps taken) or activity rates (counts/minute). Although accelerometers are without reproach in 
terms of the study of physical activity intensity in relation to health outcomes, pedometers are 
generally considered more practical for individual and population level applications, largely due 
to instrument cost and feasibility of data collection and management. Pedometers are typically 
based on a horizontal spring-suspended lever arm and on-instrument digital data presentation; 
their output correlates highly (median r=0.86) with that of different accelerometers (Tudor-
Locke, et al., 2002). Although they are not designed to directly detect physical activity intensity, 
they do provide a simple and affordable means of tracking daily physical activity volume 
(especially walking) expressed as a summary output of steps/day. An indicator of volume is 
likely sufficient when studying sedentary populations, who by definition, do not engage in high 
levels of physical activity (Tudor-Locke and Myers, 2001).  
Piezoelectric pedometers are a recent addition to the options for objective monitoring. 
Their measurement system is based on a basic accelerometer-type mechanism sensitive to 
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detecting steps taken. They typically also provide on-instrument digital data and have been 
classified as pedometers since outputs include only steps and variables derived from steps. Most 
objective monitoring instruments are worn at the waist with few notable exceptions, for example, 
the ankle mounted StepWatch Activity Monitor (SAM, originally developed by the Prosthetic 
Research Study, Seattle, WA and now distributed through CYMA Corporation, Mountlake 
Terrace, WA). The SAM is worn on one leg and detects a “stride,” or “gait cycle,” although this 
output has also been presented as steps/day. However, in order to generate a steps/day output 
comparable to waist-mounted instruments, it should be doubled.  
Expected values are normative or benchmark values that convey estimates of central 
tendency and variability and are derived from a review of published literature (Myers, 1999). 
They are necessary to facilitate research and program planning and aid in comparisons and 
interpretation of similar data (for example in surveillance efforts, and especially identifying and 
studying “unusual” samples). When we first compiled expected values of habitual pedometer-
determined physical activity in free-living samples (Tudor-Locke and Myers, 2001), we located 
12 studies that together represented heart and vascular diseases, chronic obstructive pulmonary 
disease, diabetes, joint replacement , and disabilities including blindness, physical handicaps, and 
mental retardation . From that review we concluded that adults living with chronic illnesses and 
disabilities accumulate 3,500-5,500 steps/day. In comparison, we found that relatively healthy 
adults (aged ≅20-50 years) took 7,000-13,000 steps/day. The purpose of this review is to update 
expected values for steps/day pertinent to free-living special populations. 
Methods: 
A literature search (current and verified as of January 05, 2009) began with a keyword 
(pedometer, “step counter,”  “step activity monitor” or “accelerometer” AND “steps/day”) search 
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of Medline, Cumulative Index to Nursing & Allied Health Literature (CINAHL), SportDiscus, 
and PsychInfo. A publication date limit was set from 2000, coinciding with the acceptance of the 
original review (Tudor-Locke and Myers, 2001). As unique studies were identified and 
assembled, and to the extent that it was possible, categories were assembled to generally depict 
similar illnesses and disability. Tables were generated capturing the original reference, sample 
descriptions (including sex, age descriptors as available, and verbatim descriptions of illness or 
disability), verbatim descriptions of objective monitoring instrument brands used, monitoring 
frame (i.e., number of days worn), and exact mean (or median) and standard deviation (or 
standard error) of steps/day (studies reporting distance traveled or other non-step outputs were 
not included). Inconsistencies in presentation across table columns reflect underlying 
inconsistencies in reporting across studies. Since the SAM 1) is uniquely an ankle-mounted 
accelerometer that, 2) is known to be more sensitive to low velocity stepping than waist-mounted 
pedometers (Karabulut, et al., 2005, Silva, et al., 2002, Silva, et al., 2005),  3) is more likely to 
detect “fidgeting” activities (Karabulut, et al., 2005), and 4) detects steps taken on only one leg 
differentiating itself from waist-mounted instruments that are sensitive to accelerations at both 
hips, we doubled originally reported data (after verifying that the original study did not do this) 
to make it more comparable to the traditional assessment of steps/day, and assembled relevant 
studies separately within each table.  
Ultimately, we assembled expected values for steps/day pertinent to free-living special 
populations, specifically: 1) heart and vascular diseases , 2) chronic obstructive lung disease, 3) 
diabetes and dialysis, 4) breast cancer, 5) neuromuscular diseases, 6) arthritis, joint replacement, 
and fibromyalgia, and 7) disability (including mental retardation/intellectual difficulties), and 8) 
other special populations. Wherever possible, an overall median steps/day was calculated for 
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each category (and by each instrument type, i.e., waist-mounted and ankle-mounted) considering 
at least two assembled samples (even if those samples were reported within the same study) of 
similar special populations originally reporting mean values. If only a single sample was 
identified then it necessarily stood alone as an indicator of expected values for steps/day. No 
attempt was made to weight any of the values since few variables were sufficiently detailed 
and/or consistently reported across all studies and it was decided that any attempt to weight the 
data would imply a precision of the estimate that we do not believe is appropriate or valid at this 
time.  
Heart and Vascular Diseases (Table 1) 
 Ten studies reporting expected values for habitual steps/day using waist-mounted 
instruments were identified representing populations described as living with chronic heart 
failure (Houghton, et al., 2002), coronary artery disease (VanWormer, et al., 2004), myocardial 
infarction/cardiac rehabilitation (Ayabe, et al., 2008, Izawa, et al., 2004, Savage and Ades, 
2008), peripheral arterial disease (Crowther, et al., 2007)  and/or intermittent claudication (Nasr, 
et al., 2002), hypertension (Hyman, et al., 2007, Iwane, et al., 2000), and post-stroke (Katoh, et 
al., 2002). Two studies (Crowther, et al., 2007, Houghton, et al., 2002) reported mean steps/week 
and it was necessary to divide the output by 7 in order to derive mean steps/day for comparison 
purposes. It is important to note that two of the studies (Ayabe, et al., 2008, Savage and Ades, 
2008) captured steps/day in patients actively engaged in a cardiac rehabilitation program and 
another reported steps/day in patients who continued to exercise post cardiac rehabilitation 
(Izawa, et al., 2004).  The overall median value for habitual steps/day using waist-mounted 
instruments was 4,684 steps/day. 
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 Four studies were identified that used the ankle-mounted SAM.Two focused on 
intermittent claudication (Gardner, et al., 2007, Gardner, et al., 2008) and two on post-stroke 
chronic hemiparesis (Bowden, et al., 2008, Resnick, et al., 2008). We calculated a median value 
of 6,515 for habitual steps/day using ankle-mounted instruments specifically for individuals 
living with intermittent claudication and 4,695 steps/day for post-stroke chronic hemiparesis. 
Chronic Obstructive Lung Disease (COPD; Table 2) 
 Only two studies (de Blok, et al., 2006, McGlone, et al., 2006) were indentified reporting 
expected values for habitual steps/day using waist-mounted instruments in COPD samples. Only 
one (de Blok, et al., 2006) of these studies reported mean steps/day in at least two samples (the 
other (McGlone, et al., 2006) reported median values). Therefore the computed median expected 
value for this category was 2,237 steps/day. No studies of COPD samples were identified using 
ankle-mounted instruments. 
Diabetes and Dialysis (Table 3) 
 Seven unique studies using waist-mounted instruments were identified focused on Type 2 
diabetic populations (Araiza, et al., 2006, Bjorgaas, et al., 2005, Matsushita, et al., 2005, 
Richardson, et al., 2007, Strycker, et al., 2007, Tudor-Locke, 2001, Tudor-Locke, et al., 2002), 
and another study captured both Type 1 and Type 2 diabetes (Smaldone, et al., 2006). We also 
included a single study of a dialysis population (Zamojska, et al., 2006) in this category, since 
diabetes is a leading cause of dialysis. The calculated mean expected value for studies of Type 2 
diabetes using waist-mounted instruments was 6,342 steps/day.  
 Three studies (Kanade, et al., 2006, Lemaster, et al., 2008, Smith, et al., 2004)  were 
identified using ankle-mounted instruments (specifically the SAM accelerometer). Type of 
diabetes was not identified in any of these studies, however, based only on reported age we 
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assumed they focused on Type 2 diabetes. One study reported data weighted by number of days 
provided by participants (Lemaster, et al., 2008). The median value for steps/day obtained from 
this ankle-mounted instrument was 7,407 steps/day. 
Breast Cancer (Table 4) 
 Five studies of habitual steps/day using waist-mounted instruments in breast cancer 
survivors were identified (Irwin, et al., 2008, Matthews, et al., 2007, Rogers, et al., 2005, 
Vallance, et al., 2007, Wilson, et al., 2005). The study that used a waist-mounted accelerometer 
(Matthews, et al., 2007) reported steps/day values after censoring those values coinciding with 
accelerometer activity counts below 260 counts/minute. A third study focused on breast cancer 
patients undergoing treatment (Rogers, et al., 2005). The median expected value for breast 
cancer survivors calculated was 7,409 steps/day. No studies were identified using ankle-mounted 
instruments. 
Neuromuscular Diseases (Table 5) 
 Two original articles were identified reporting steps/day determined by waist-mounted 
instruments (Gosney, et al., 2007, Motl, et al., 2006). A third one presented steps/day data only 
in a figure (Kilmer, et al., 2005). We successfully contacted the first author directly to obtain the 
exact mean and SD for steps/day. Therefore, the median expected value for this category was 
5,887 steps/day.  
Two studies were identified that used the ankle-mounted instrument to detect steps/day in 
individuals living with neuromuscular diseases (Busse, et al., 2004, Xanthopoulos, et al., 2008). 
The median value for this category was 6,006 steps/day. 
Arthritis, Joint Arthroplasty and Fibromyalgia (Table 6) 
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 Eight unique studies were identified that presented habitual steps/day using waist-
mounted instruments in individuals with arthritis (Talbot, et al., 2003), joint (hip or knee) 
arthroplasty (Bennett, et al., 2008, Goldsmith, et al., 2001, Schmalzried, et al., 2000, Silva, et al., 
2002, Silva, et al., 2005), a combination of arthritis and arthroplasty (Ono, et al., 2007), or 
fibromyalgia (Fontaine and Haaz, 2007). The median expected value for individuals with 
arthritis was 4,086 steps/day and for those with joint arthroplasty it was 4,892 steps/day.The 
single study that included a combination of arthritis and arthroplasty (Ono, et al., 2007) (without 
distinctly presenting the data as such) was not considered in the calculation for either the arthritis 
or the arthroplasty expected values. 
 Three studies were identified that used the ankle-mounted SAM accelerometer. Two 
focused on individuals with hip arthroplasties (Schmalzried, et al., 2000, Silva, et al., 2002) and 
the third assessed individuals living with hip or knee osteoarthritis (Brandes, et al., 2008). The 
median value for hip replacement was 10,494 steps/day. 
Disability (Table 7) 
 We located five unique studies of disabled individuals reporting steps/day using waist-
mounted instruments (Mitsui, et al., 2003, Mitsui, et al., 2006, Peterson, et al., 2008, Stanish and 
Draheim, 2005, Temple, 2007). Two studies (Mitsui, et al., 2003, Mitsui, et al., 2006) examined 
older (i.e., over 70 years) disabled individuals and three studies examined younger (i.e., between 
30 and 40 years) individuals with mental retardation/intellectual disability (Peterson, et al., 2008, 
Stanish and Draheim, 2005, Temple, 2007). The median expected value for older individuals 
with disability was 1,214 steps/day and 7,787 steps/day for younger individuals with mental 
retardation/intellectual disability. 
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 Six studies using the ankle-mounted SAM accelerometer were identified. Three reported 
steps/day values for individuals living with prostheses (Kanade, et al., 2006, Rosenbaum, et al., 
2008, Stepien, et al., 2007), one reported values for individuals who had suffered an incomplete 
spinal cord injury (Bowden and Behrman, 2007), one focused on females post-hip fracture 
(Resnick, et al., 2007), and another focused on older adults reporting functional limitations 
(Cavanaugh, et al., 2007). The median value for individuals living with prostheses was 6,126 
steps/day. No other median values were computed. 
Other Special Populations (Table 8) 
 HIV infection is a chronic disease and we identified a single study that used both waist-
mounted pedometers (DigiWalker Model 200) and accelerometers (ActiGraph Model GT7164) 
(Ramirez-Marrero, et al., 2008). The computed median expected values for waist-mounted 
instruments combined from these four samples within the same study is 7,545 steps/day.  
Another study was identified that focused on  older community-dwelling individuals living with 
multiple chronic illnesses (Ashe, et al., 2007). The most frequently reported illnesses/disabilities 
were high blood pressure (58%), cataracts (55%), and osteoarthritis (50%). Pedometer-
determined physical activity was not presented by illness. However, steps/day for the total 
sample averaged 6,078±4,031. 
Discussion 
An amalgamation of expected values of steps/day focused on special populations, 
specifically those defined by chronic illness or disability, was missing from the scientific 
literature. We ultimately located 60 unique studies of free-living special populations published 
since 2000 that provided descriptive data necessary to address this gap. Forty-three studies used 
waist mounted instruments, specifically, waist-mounted pedometers (n=31), accelerometers 
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(n=9), both pedometers and accelerometers (n=2) or piezoelectric pedometers (n=1). Another 16 
studies used the ankle-mounted SAM accelerometer  and a single study used both waist- and 
ankle-mounted instruments (Silva, et al., 2002). At least 19 (33%) studies clearly identified using 
a Yamax pedometer model (i.e., Yamasa, Yamax, Digi-walker), followed by Sportline (3 studies 
or 5%). There were seven studies that did not report a pedometer brand. The Lifecorder was the 
most frequently used accelerometer (7 studies or 12%) followed by the ActiGraph (3 studies or 
5%). Monitoring frames (where reported) ranged from 2 days to 2 weeks; the modal length of 
time was 7 days (29 studies, or 50%).  
Figure 1 is a visual presentation of expected values for waist-mounted instrument for 
each of the categories identified. Despite the fact that the assembled values reflect a fragmented 
and at times sparse literature representing differing measurement protocols (including brands of 
pedometers used and monitoring frames), obvious patterns of habitual pedometer-determined 
physical activity emerged. The lowest median values for pedometer-determined steps/day are 
found in disabled older adults (1,214 steps/day) followed by people living with COPD (2,237 
steps/day) and fibromyalgia (2,337 steps/day). These very low values are not surprising since 
these are the very individuals we can expect to be limited in habitual physical activity by the 
nature of their illness/disability. The highest values were seen in individuals with Type 1 
diabetes (8,008 steps/day), mental retardation/intellectual disability (7,787 steps/day), HIV 
(7,545 steps/day), and breast cancer survivors (7,409 steps/day). These populations are relatively 
younger and otherwise healthy and less restricted in their daily physical activity.  Scrutinizing 
the breast cancer category alone reveals that only one study examined patients undergoing 
treatment. The remaining four studies were conducted with survivors of breast cancer, who we 
can assume are living their lives without the same physical limitations associated with other 
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chronic diseases. Despite these relatively higher values for steps/day within populations living 
with chronic diseases or disabilities, as stated earlier, we can expect otherwise healthy adults to 
take between 7,000-13,000 steps/day (Tudor-Locke and Myers, 2001), so that most of the values 
presented herein appear relatively lower in comparison.  In agreement with these general 
findings, self-report data also suggest that individuals with Type 2 diabetes do not engage in 
regular physical activity (Morrato, et al., 2007), and cancer survivors are more likely to be 
physically inactive than those who have never had cancer (Coups and Ostroff, 2005). Other 
patterns were also evident: physical activity differs by type of diabetes (Type 1 at 8,008 
steps/day vs. Type 2 at 6,291 steps/day) and those who are most ill (i.e., receiving dialysis) are 
the least active (3,448 steps/day).   
In 2004, Tudor-Locke and Bassett, Jr. established preliminary pedometer-determined 
physical activity cut points for healthy adults: 1) <5,000 steps/day (sedentary); 2) 5,000-7,499 
steps/day (low active); 3) 7,500-9,999 (somewhat active); 4) 10,000-12,499 (active); and 5) 
≥12,500 steps/day (highly active). These categories were reinforced in 2008 (Tudor-Locke, et al., 
2008). Since these cut points were established with the measurement parameters of research 
quality waist-mounted instruments in mind, we only use these to interpret the similarly reported 
data herein. According to these cut points, individuals living with heart and vascular diseases, 
COPD, arthritis, and fibromyalgia, and those undergoing dialysis or who are disabled older 
adults, are considered sedentary. Individuals living with Type 2 diabetes, neuromuscular 
diseases, and multiple chronic illnesses (otherwise unspecified) are considered low active. And 
individuals living with Type 1 diabetes, HIV, breast cancer, and mental retardation/intellectual 
disabilities are considered somewhat active. Since the lowest echelon labeled sedentary is 
actually quite broad (it covers 5,000 steps whereas all other categories span only 2,500 steps, 
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with the exception of the highest echelon), and since it is apparent that there are individuals who 
take considerably few steps/day than the simple 5,000 steps/day cut point, we propose that the 
previously established sedentary category be cut into <2,500 steps day (indicative of basal 
physical activity) and 2,500 to <5,000 steps/day (indicative of limited physical activity) (Tudor-
Locke, et al., in press). Using these adaptations, disabled older adults and individuals living with 
COPD or fibromyalgia exhibit basal physical activity and those living with heart and vascular 
disease or arthritis, or undergoing dialysis, display limited physical activity. 
Figure 2 presents expected values for the ankle-mounted SAM across identified 
conditions. It is important to emphasize that these categories emerged from the studies identified 
for this instrument and therefore a lack of direct comparison between numbers and naming of the 
categories must be expected. The lowest values are for incomplete spinal cord injury (3,280 
steps/day) and post-stroke (4,695 steps/day). The highest values are observed for arthritis (9,564 
steps/day) and joint replacement (10,438 steps/day). A direct comparison with waist-mounted 
instruments is not always possible since studies have independently pursued different samples. In 
the most comparable categories, waist-mounted vs. ankle-mounted expected values are: 6,291 vs. 
7,407 steps/day for Type 2 diabetes, 5,887 vs. 6,006 for neuromuscular diseases, 4,086 vs. 9,564 
for arthritis, and 4,883 vs.10,438 for joint replacement.  
Although the studies assembled herein used a variety of objective monitors, the majority 
reported using instruments that have been previously validated. The Yamax pedometer is 
considered a criterion research quality pedometer (Schneider, et al., 2004), the Lifecorder’s 
validity is well documented (Crouter, et al., 2003, Schneider, et al., 2004), and the ActiGraph has 
been adopted by national surveillance strategies (Troiano, et al., 2008) and is perhaps the most 
utilized accelerometer in research today. In addition the SAM is considered to be an important 
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objective monitor specifically sensitive to low force threshold gaits associated with age and 
impairment (Karabulut, et al., 2005, Silva, et al., 2002, Silva, et al., 2005). That being said, we 
firmly believe that it was prudent to present data from waist-mounted and ankle-mounted 
instruments separately as the absolute difference in detected steps was likely to impair direct 
comparisons. Although it plausible that at least some disease/disability-related reduction in 
steps/day is complicated by slower gaits with advanced disability, the pattern displayed is 
congruent with what we know from other assessments of physical activity in these populations, 
including doubly labeled water (Kulstad and Schoeller, 2007). Ultimately, the choice of which 
instrument is best to capture the unique ambulatory activity patterns of a population is a function 
of the research question, participant burden, and resources available to the researcher or 
practitioner. By assembling expected data here representing a number of instruments, we hope to 
establish useful benchmarks and to facilitate comparisons between and across populations.                                             
It is important to emphasize here that expected values convey estimates of central 
tendency and variability for habitual steps/day derived from a review of published literature. 
Their use does not imply any association with what people with such diseases or disabilities 
“should” be taking (i.e., an “indicator,” “cut point,” or “threshold” value). The end product of 
assembled expected values will be useful to researchers and practitioners who work with 
individuals living with chronic illness and disability. For example, a clinician who is familiar 
with such expected values can identify those individuals who are most likely to benefit from a 
physical activity intervention. Researchers can use the values to assist with study recruitment and 
screening procedures as well as calculate sample sizes and conduct power analyses for their 
studies. That being said, it is important to acknowledge that these estimates are largely based on 
small, non-representative samples thus limiting external validity. It is quite possible that the 
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results represent individuals who are less severely affected by their condition and are more 
capable of consenting and adhering to wearing an objective monitor for several days. There is 
little evidence to draw firm conclusions about degrees of morbidity and steps/day. Although 
extremely useful, these expected values should be used with due caution. Full-scale surveillance 
research with nationally-representative samples is needed to obtain true estimates, however, the 
cost of such an endeavor is currently beyond reach for many of these special populations. 
Regardless, the expected values assembled herein offer an important resource that should be 
expanded and refined as future studies inevitably emerge. 
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Figure 1. Expected values for steps/day in special populations (living with chronic disease or 
disability) using waist-mounted instruments 
 
 Parentheses note number of samples expected value is based upon 
 
 27 
Figure 2. Expected values for steps/day in special populations (living with chronic disease or 
disability) using an ankle-mounted instrument 
 
 
Parentheses note number of samples expected value is based upon 
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Table 1. Expected values for habitual steps/day in free-living individuals living with heart and vascular diseases 
Study Sample Age (years) Instrument 
Monitoring 
Frame Mean Steps/day 
SD (unless 
indicated 
as SE) 
Waist-mounted instruments 
Iwane et al. 
(2000) 
 
17 hypertensive males 
 
 
48.7±1.9 
 
 
Pedometer: Hello 
Walk, Tanita, 
Tokyo, Japan 
Not reported 
 
 
5,790 
 
 
SE 458 
 
 
Houghton et 
al. (2002) 
 
 
31 males, 5 females with 
stable mild-moderate 
chronic heart failure 
 
Mean 69  
Range 48-80 
 
 
Pedometer: 
Digiwalkers, 
Steiner, Brentford, 
UK 
14 days 
 
 
 
4342.4a 
 
 
 
SE 734.1a 
 
 
 
Katoh et al. 
(2002) 
 
 
16 male and 4 female 
community dwelling 
post-stroke patients 
 
64±9 years 
old 
 
 
Accelerometers: 
Kenz Life Corder, 
Suzuken, Co., 
Nagoya, Japan 
12±4 days 
 
 
 
4346 
 
 
 
2933 
 
 
 
Nasr et al. 
(2002) 
 
 
 
39 males, 11 females 
with intermittent 
claudication 
 
 
Median 67 
Range 62-73 
 
 
 
Pedometer: 
Sportline 345, 
Sportline, 
Campbell, CA, 
USA 
7 days 
 
 
 
 
Median 5728 
 
 
 
 
Not 
reported 
 
 
 
Izawa et al.  
(2004) 
 
 
 
 
90 acute myocardial 
infarction patients who 
continued to exercise 
post cardiac 
rehabilitation, 19 who 
quit 
63.5±10.1 
 
 
 
 
 
Accelerometer: 
Kenz Lifecorder, 
Suzuken, Nagoya, 
Japan 
 
 
7 days 
 
 
 
 
 
Continued exercisers: 
9252.5 
 
Quitters: 4246.2 
 
 
3046.6 
 
2024.9 
 
 
Van 
Wormer et 
al. (2004) 
14 males, 8 females with 
coronary artery disease 
 
29.42±7.18 
 
 
Pedometer: Brand 
not reported 
 
Not reported 
 
 
6152.1 
 
 
2927.0 
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Table 1. Expected values for habitual steps/day in free-living individuals living with heart and vascular diseases (continued) 
 
Crowther et 
al. (2007)   
 
 
28 patients with 
peripheral arterial disease 
presenting with 
intermittent claudication 
69.9±1.5 
 
 
Pedometer: Yamax 
DigWalker SW-
700, Yamax Corp, 
Tokyo, Japan 
7 days 
 
 
 
4156.1a 
 
 
 
572.6 a 
 
 
 
Hyman et al. 
(2007) 
 
 
92 AA males and 189 
AA females, current 
smokers with 
hypertension 
Range 45-65 
 
 
 
Pedometer: Brand 
not reported 
 
 
1 week 
 
 
 
3624.4b 
3306.0b 
3933.0b 
 
2917.5b 
2785.3b 
3363.6b 
 
Ayabe et al. 
(2008) 
 
 
53 males, 24 females, 
cardiacrehabilitation 
program participants 
68.1±9.2 
 
 
Accelerometer: 
Lifecorder, 
Suzuken Co., 
Tokyo Japan 
7 days 
 
 
6752 
 
 
2659 
 
 
Savage et al. 
(2008) 
 
 
 
 
 
 
79 males, 28 females at 
entry to cardiac 
rehabilitation 
 
 
 
 
 
63±10 
 
 
 
 
 
 
 
Pedometer: 
Walk4Life, Inc, 
Plainfield, Illinois 
 
 
 
 
 
 
7 days 
 
 
 
 
 
 
 
Males non-rehab day 
5515 
Males rehab day  
7580 
Females non-rehab day 
4684 
Females rehab day 
6755 
4684 
 
3409 
 
2863 
 
3330 
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Table 1. Expected values for habitual steps/day in free-living individuals living with heart and vascular diseases (continued) 
Ankle-mounted instruments 
Gardner et 
al.(2008) 
 
 
 
54 males, 44 females 
with intermittent 
claudication 
 
 
Range 50-90 
 
 
 
 
Accelerometer: 
Step Watch 3, 
Cyma Inc, 
Mountlake Terrace, 
WA 
7 days 
 
 
 
 
6298 
 
 
 
 
3114 
 
 
 
 
Gardner et 
al. (2007) 
 
 
 
133 patients with 
intermittent claudication 
 
 
 
67±10 
Range 50-90 
 
 
 
Accelerometer: 
Step Watch 3, 
Cyma Inc, 
Mountlake Terrace, 
WA 
7 days 
 
 
 
 
6732 
 
 
 
 
3388 
 
 
 
 
Bowden et 
al. (2008) 
 
 
 
 
 
 
 
 
48 males, 11 females 
with chronic hemiparesis 
(>6 months poststroke) 
 
 
 
 
 
 
 
61.9±10.8 
 
 
 
 
 
 
 
 
 
Accelerometer: 
StepWatch Activity 
Monitor, OrthoCare 
Innovations, 
Washington, DC 
 
 
 
 
 
5 days 
 
 
 
 
 
 
 
 
 
household ambulators 
(walking 
speed<0.4m/s) 2822 
limited community 
ambulators (walking 
speed 0.4-0.8 m/s) 
 5336 
community ambulators 
(walking speed>0.8 
m/s) 7318 
1606  
 
 
 
2386.6 
 
 
2894.8 
Resnick et 
al. (2008) 
 
 
51 males, 36 females 
with chronic hemiparetic 
stroke (>6 months 
poststroke) 
63.7±12.3 
 
 
 
Accelerometer: 
Step Watch 
Activity Monitor 
(SAM) 
2 days 
 
 
 
4055.17 
 
 
 
2401.2 
 
 
 
AA = African American; areported as steps/week in paper, steps/day imputed by dividing by 7; bvalues for otherwise equivalent groups 
at baseline 
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Table 2. Expected values for habitual steps/day in free-living individuals living with chronic obstructive lung disease (COPD) 
 
Study Sample Age (years) Instrument 
Monitoring 
frame Mean steps/day 
SD (unless 
indicated 
as SE) 
Waist-mounted instruments 
de Blok et 
al. (2006) 
 
 
 
 
16 patients with 
COPD (sex 
breakdown not 
reported for this 
subsample who 
wore pedometers) 
Range 40-85  
 
 
 
 
 
Pedometer: Yamax 
DigiWalker, SW-200 
Tokyo, Japan 
 
 
 
7 days 
 
 
 
 
 
Experimental group: 2140a 
Control group: 2334a 
 
 
 
 
Not 
reported 
McGlone et 
al. (2006) 
 
74 males, 50 
females with COPD 
 
70±8 
Range 50-89 
 
Pedometer: HJ 003 
Omron Healthcare, 
Singapore 
7 days 
 
 
Median 3716 
 
 
Not 
reported 
avalues for otherwise equivalent groups at baseline 
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Table 3. Expected values for habitual steps/day in free-living individuals living with diabetes) or dialysis  
Study Sample Age (years) Instrument 
Monitoring 
frame Mean steps/day 
SD 
(unless 
indicated 
as SE) 
Waist-mounted instruments 
Tudor-
Locke et al. 
(2001) 
3 males, 6 females with 
Type 2 diabetes 
 
53±6 
 
 
Pedometer: Yamax 
Digiwalker SW-200 
 
3 days 
 
 
6342 
 
 
2244 
 
 
Tudor-
Locke et al.  
(2002) 
98 males, 62 females 
with Type 2 diabetes 
 
52.4±5.3 
 
 
Pedometer: Yamax 
Digiwalker SW-
200, Accusplit, CA 
3 days 
 
 
6662 
 
 
3077 
 
 
Matsushita 
et al. (2005) 
 
46 males, 16 females 
with Type 2 diabetes 
 
58.1±9.5 
Range 33-77 
 
Accelerometer: 
Suzuken, 
Lifecorder 
1 week 
 
 
9030a 
9049a 
8809a 
SE 686a 
SE 652a 
SE 665a 
Bjorgaas et 
al. (2005) 
 
 
29 males with Type 2 
diabetes 
 
 
57.4±7.8 
 
 
 
Pedometer: Yamax 
Digi-Walker ML 
AW-320, Yamax, 
Tokyo, Japan 
3 days 
 
 
 
4194 
 
 
 
Not 
reported 
 
 
Araiza et al. 
(2006) 
 
 
30 patients with Type 2 
diabetes mellitus (sex not 
reported) 
 
Range 33-69  
 
 
 
Pedometer: Yamax 
Digwalker SW-701, 
New Lifestyles, 
Kansas City, MI 
10 days 
 
 
 
6239b 
7220b 
 
 
2985b 
2792b 
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Table 3. Expected values for habitual steps/day in free-living individuals living with diabetes or dialysis (continued) 
Smaldone et 
al. (2006) 
 
 
38 males, 63 females 
with Type 1 diabetes 
60 males, 47 females 
with Type 2 diabetes 
44±12.4 
 
57±9.2 
Pedometer: Brand 
not reported 
 
 
3 days 
 
 
 
Type 1 diabetes 8008 
 
Type 2 diabetes 5491 
3781 
 
3828 
Zamojska et 
al. (2006) 
 
 
33 male, 27 female 
chronic haemodialysis 
patients 
 
60±13 
 
 
 
Pedometer: Oregon 
Scientific 
PE316CA, 
Portland, OR 
2 days 
 
 
 
3448c 
 
 
 
1178.5c 
 
 
 
Strycker et 
al. (2007) 
 
270 postmenopausal 
females with type 2 
diabetes  
40- 70+ 
 
 
Pedometer: Yamax 
Model SW-701 
 
7 days 
 
 
4352 
 
 
2981 
 
 
Richardson 
et al. (2007) 
10 males, 20 females 
with type 2 diabetes 
Mean 52.5 
 
Accelerometer: 
Omron HJ-720IT 7 days 4596 1794 
Ankle-mounted instruments 
Smith et al. 
(2004)   
 
57 males with diabetes 
 
 
Mean 68 
Range 41-85 
 
Accelerometer: 
Step Activity 
Monitor (SAM) 
14 days 
 
 
6585.6 
 
 
4073.2 
 
 
Kanade et 
al. (2006) 
 
 
 
 
19 males, 2 females with 
diabetic neuropathy 
without plantar ulceration 
 
 
 
62.9±6.2 
 
 
 
 
 
Accelerometer: 
Stepwatch Activity 
Monitors (SAM; 
Prosthetics 
Research Study, 
Seattle, WA) 
7 days 
 
 
 
 
 
8228 
 
 
 
 
 
3864 
 
 
 
 
 
LeMaster et 
al.(2008) 
 
 
 
40 males, 39 females 
with diabetic peripheral 
neuropathy 
 
 
≥50 
 
 
 
 
Accelerometer: 
StepWatch, 
OrthoCare 
Innovations, 
Washington, DC 
14 days 
 
 
 
 
control group baseline 
6700d 
 
intervention group baseline 
6670d 
SE 494d 
 
 
SE 492d 
avalues reported by HbA1c tertiles; bvalues for otherwise equivalent groups at baseline; cmean and SD divided by 2 since data was 
originally reported per 48 hours; ddata weighted by days worn 
 35 
Table 4. Expected values for habitual pedometer-determined physical activity in free-living breast cancer survivors or breast cancer 
patients undergoing treatment 
Study Sample Age (years) Instrument 
Monitoring 
frame Mean steps/day 
SD 
(unless 
indicated 
as SE) 
Waist-mounted instruments 
Wilson et al. 
(2005) 
24 AA breast cancer 
survivors 
Mean 55 
 
Pedometer: Brand 
not reported  
Not reported  
 
4791 
 
Not 
reported 
Rogers et al. 
(2005) 
 
 
15 breast cancer patients 
undergoing treatment 
 
 
75% ≥ 50 
years 
 
 
Pedometer: Yamax 
SW-701 Digi-
Walker, Yamax, 
Tokyo, Japan 
7 days 
 
 
 
5525 
 
 
 
2906 
 
 
 
Vallance et 
al. (2007) 
 
 
 
337 breast cancer 
survivors 
 
 
 
Mean 58 
Range 30-90 
 
 
 
Pedometer: Digi-
Walker SW 200 
(New Lifestyles 
Inc, Lee's Summit, 
MO) 
7 days 
 
 
 
 
7938a 
8306a 
8476a 
7993a 
 
3906a 
3831a 
3248a 
3559a 
 
Irwin et al. 
(2008) 
75 postmenopausal breast 
cancer survivors 40-75 
Pedometer: Brand 
not reported 7 days 
Exercisers 5145a 
Usual care 5342a 
2312a 
2744a 
Matthews et 
al (2007) 
23 breast cancer 
survivors ≥ 45 years 
Accelerometer: 
Manufacturing 
Technology (MTI, 
Fort Walton Beach, 
FL) Actigraph 7 days 
Usual care 5939a,b 
Intervention 7409.4a,b 
2203.5a,b 
2791.1a,b 
AA = African American; avalues for intervention groups otherwise equivalent at baseline; bsteps/day values after censoring those 
values coinciding with accelerometer activity counts below 260 counts/minute 
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Table 5. Expected values for habitual steps/day in free-living individuals living with progressive neuromuscular diseases 
Study Sample Age (years) Instrument 
Monitoring 
frame Mean steps/day 
SD (unless 
indicated as 
SE) 
Waist-mounted instruments 
Kilmer et al. 
(2005) 
 
 
12 males, 18 females 
with slowly progressive 
neuromuscular diseases 
 
49.9±13.2 
 
 
 
Pedometer:Yamax 
Digi-Walker, 
Yamax Corp, 
Tokyo, Japan 
3 days 
 
 
 
4323.8a 
 
 
 
2216.9 a 
 
 
 
Motl et al. 
(2006) 
 
 
2 males, 28 females with 
multiple sclerosis 
 
 
42.3±9.5 
 
 
 
Pedometer: Yamax 
SW-200, Yamax 
Corporation, 
Tokyo, Japan 
7 days  
 
 
 
7097 
 
 
 
3931 
 
 
 
Gosney et al. 
(2007) 
 
 
23 males, 173 females 
with multiple sclerosis 
 
 
46.1±9.8 
 
 
 
Pedometer: Yamax 
SW-200, Yamax 
Corporation, 
Tokyo, Japan 
7 days  
 
 
 
5887 
 
 
 
3218 
 
 
 
Ankle-mounted instruments 
Busse et al. 
(2004) 
 
 
 
 
 
 
5 males, 6 females mixed 
neurology patients 
10 females with muscular 
sclerosis 
7 males, 3 females with 
Parkinson's disease 
6 males, 4 females with 
muscular dystrophy 
59.4±13.4 
 
37.9±10.1 
 
67.1±8.2 
 
52.1±12.5 
Accelerometer: 
Step Watch, 
Cymatech, Seattle, 
WA 
 
 
 
 
7 days 
 
 
 
 
 
 
 
5922 
 
5970 
 
7636 
 
6006 
Not reported 
 
 
 
 
 
 
Xanthopoulos 
et al. (2008) 
 
 
10 males, 6 females with 
idiopathic Parkinson's 
disease 
 
71±11 
 
 
 
Accelerometer: 
CYMA step 
activity monitor 
(SAM) 
2 days 
 
 
 
8756 
 
 
 
4114 
 
 
 
a exact values obtained from first author of original publication 
Table 6. Expected values for habitual steps/day in free-living individuals living with arthritis, joint arthroplasty, or fibromyalgia  
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Study 
 
Sample 
 
Age (years) 
 
Instrument 
 
Monitoring 
frame 
Mean steps/day 
 
SD (unless 
indicated as 
SE) 
Waist-mounted instruments 
Schmalzried 
et al. 
(Schmalzrie
d, et al., 
2000) 
14 males, 17 females 
with total hip 
replacements 
Mean 72 
Range, 46-85 
Pedometer: Brand 
not reported Not reported  6795 3762 
Goldsmith 
et al. (2001) 
29 males, 25 females 
THA out-patients 
Mean 57.7 
Range 17-73 
Pedometer: Brand 
not reported 
Not reported 
 
7815 
 Not reported 
Silva et al. 
(2002) 
 
14 males, 19 females 
with well-functioning hip 
arthroplasties 
71.5±9.7 
 
 
Pedometer: 
Sportline, 
Campbell, CA 
4 days 
 
 
6878a 
 
 
3736a 
 
 
Talbot et al. 
(2003) 
 
 
 
 
 
 
 
4 males, 13 females with 
OA in one or both knees 
assigned to a pedometer 
group 
 
4 males, 13 females with 
OA in one or both knees 
assigned to education 
group 
69.5±6.74 
 
 
 
 
70.76±4.71 
 
 
 
Pedometer: New 
Lifestyles Digi-
Walker SW-200, 
Yamax, Tokyo, 
Japan 
 
 
 
 
72 hours 
 
 
 
 
 
 
 
 
3519 
 
 
 
 
4652 
 
 
 
2603 
 
 
 
 
2622 
 
 
 
Silva et al. 
(2005) 
 
131 patients with either 
THA or TKA 
 
57.6±12.8 
Range 23-82 
 
Pedometer: 
Sportline, 
Campbell, CA 
7 days 
 
 
5737 
 
 
1650 
 
 
Ono et al. 
(2007) 
 
 
61 patients with OA in 
one or more hips 
54% with THA 
 
53.3±11.3 
 
 
 
Accelerometer: 
Lifecorder, 
Suzuken Co., 
Nagoya, Japan 
At least 5 days 
 
 
 
6309 
 
 
 
2392 
 
 
 
Fontaine et 
al. (2007) 
 
22 participants with 
fibromyaliga assigned to 
a lifestyle intervention 
48±10 
 
 
Pedometer: 
Accusplit Eagle 
Activity Pedometer, 
Not reported 
 
 
2337 
 
 
427 
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   San Jose, California    
Bennett et 
al. (2008) 
 
 
 
100 patients 10 years 
post hip replacement 
 
 
 
70.3±6.9 
 
 
 
 
Pedometer: FitPro 
Yamax, Japan 
 
 
 
14 days 
 
 
 
 
55-64 years 4873 
65-69 years 4892 
70-74 years 3440 
75-79 years 3428 
>80 years 2213 
2810 
3037 
2023 
1604 
777 
Ankle-mounted instruments 
Schmalzried 
et al. (2000) 
 
 
 
14 males, 17 females 
with total hip 
replacements 
 
 
Mean 72 
Range, 46-85 
 
 
 
Accelerometer: 
Step Activity 
Monitor (SAM), 
Prosthetic Research 
Study, Seattle, WA 
Not reported 
 
 
 
 
10550 
 
 
 
 
4416 
 
 
 
 
Silva et al. 
(2002) 
 
 
 
14 males, 19 females 
with well-functioning hip 
arthroplasties 
 
 
71.5±9.7 
 
 
 
 
Accelerometer: 
Step Activity 
Monitor (SAM), 
Prosthetic Research 
Study, Seattle, WA 
4 days 
 
 
 
 
10438 
 
 
 
 
4388 
 
 
 
 
Brandes et 
al. (2008) 
 
 
9 males, 17 females with 
hip or knee osteoarthritis 
 
 
58.6±13.4 
 
 
 
Accelerometer: 
Step Activity 
Monitor 3.0 (SAM) 
Cyma Corp., WA 
7 days 
 
 
 
9564 
 
 
 
4232 
 
 
 
OA=osteoarthritis, THA= total hip arthroplasty, TKA=total knee arthroplasty; areported pedometer data as “cycles/day” therefore 
multiplied by 2 to convert back to steps/day 
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Table 7. Expected values for steps/day in free-living individuals living with disability or mental retardation/intellectual disability 
 
Study Sample Age (years) Instrument 
Monitoring 
frame Mean steps/day 
SD 
(unless 
indicated 
as SE) 
Waist-mounted Instrument - Older 
Mitsui et al.  
(2003) 
 
 
8 male, 7 female, 
disabled attending a day-
care center 
 
76.2±2.2 
 
 
 
Accelerometer: 
Lifecorder, Suzuken, 
Nagoya, Japan 
7 days 
 
 
 
1056 
 
 
 
 SE 243 
 
 
 
Mitsui et al. 
(2006) 
 
 
19 male, 23 female, 
"variously disabled" 
 
 
78.8±1.1 
 
 
 
Accelerometer: 
Lifecorder, Suzuken, 
Nagoya, Japan 
7 days 
 
 
 
1371 
 
 
 
SE 235 
 
 
 
Waist-mounted Instruments Younger 
Stanish et al. 
(2005) 
 
 
 
65 males, 38 females 
with mental retardation 
 
 
 
males 
35.9±11.2 
 
females 
39.7±9.5 
Pedometer: Yamax 
Digiwalkers SW-500 and 
SW-700 
 
 
7 days 
 
 
 
 
Males 7958 
 
 
Females 7616 
 
3888 
 
 
3804 
 
Temple et al. 
(2007) 
 
 
 
 
18 males, 19 females 
with intellectual 
disability 
 
 
 
males  
32.6±9.4 
 
females 
34.1±7.1 
 
Pedometer: Yamax digi-
walker SW-700, New 
Lifestyles, Inc., Lee's 
Summit, Missouri, USA 
7 days 
 
 
 
 
 
8,100.5 
 
 
 
 
 
3735.4 
 
 
 
 
 
Peterson et 
al. (2008) 
 
 
63 males and 68 females 
with mild to moderate 
intellectual disability 
 
37.2±11.6 
 
 
 
Piezoelectric pedometer:  
Omron Model HJ700IT, 
Omron Healthcare, 
Kyoto, Japan 
7 days 
 
 
 
6621 
 
 
 
3366 
 
 
 
Ankle-mounted instruments 
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Kanade et al. 
(2006) 
 
 
18 males, 3 females with 
diabetic neuropathy and 
trans-tibial amputation, 
prothetic 
63.8±5.7 
 
 
 
Accelerometer: 
StepWatch 3 Activity 
Monitor 
 
7 days 
 
 
 
3882 
 
 
 
2168 
 
 
 
Bowden et 
al. (2007) 
 
 
9 males, 2 females with 
incomplete spinal cord 
injury 
Range 21-63 
 
 
 
Accelerometer:Step 
Activity Monitor (SAM), 
Cyma Corporation, 
Seattle, WA 
4 days 
 
 
 
3280.4 
 
 
 
867.4 
 
 
 
Cavanaugh 
et al. (2007) 
 
 
 
5 males, 7 females 
reporting functional 
limitations 
 
 
79.3±4.5 
 
 
 
 
Accelerometer: 
StepWatch 3 Activity 
Monitor (SAM; Cyma 
Corporation, Mountlake 
Terrace, WA) 
6 days 
 
 
 
 
7681.5 
 
 
 
 
SE 844.4 
 
 
 
 
Resnick et 
al. (2007) 
51 females post-hip 
fracture 
79.7±6.7 
 
Accelerometer: Step 
Activity Monitor (SAM) 
2 days 
 
8120 
 
SE 1246 
 
Stepien et al. 
(2007) 
 
 
 
60 males, 17 females 
unilateral lower limb 
amputees following 
prothetic rehabilitation 
 
60±15 
 
 
 
Accelerometer: 
Stepwatch Activity 
Monitor (SAM), 
Prosthetics Research 
Study, Seattle, WA 
6 days 
 
 
 
 
6126 
 
 
 
 
3786 
 
 
 
 
Rosenbaum 
et al. (2008) 
 
 
14 male, 8 female with 
modular prostheses 
following malignant 
bone tumor treatment 
34.5±18.4 
 
 
 
Accelerometer: SAM 
Step Activity Monitor, 
Cyma, Inc., Seattle, OR 
 
7 days 
 
 
 
9572 
 
 
 
3540 
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Table 8. Expected values for steps/day in free-living individuals living with other disease or disabilities 
Study Sample Age (years) Instrument 
Monitoring 
Frame Mean Steps/day 
SD (unless 
indicated 
as SE) 
Waist-mounted instruments 
Ramirez-
Marrero et 
al. (2008) 
 
 
 
 
 
35 Hispanic males and 
23 Hispanic females 
 
 
 
 
 
 
 
46.5±8.8 
 
 
 
 
 
 
 
 
Pedometer: 
DigiWalker Model 
200 
 
 
AND 
 
Accelerometer: 
ActiGraph Model 
GT7164 
7 days 
 
 
 
 
 
 
 
 
Males 7594 
Females 7495 
 
 
 
 
 
Males 7151 
Females 7886 
2817 
2540 
 
 
 
 
 
2589 
2662 
Ashe et al. 
(2007) 
 
70 males, 130 females 
living with multiple 
chronic illnesses 
 
 
74±5.7 
 
 
 
 
Pedometer: New 
Lifestyles 
DigiWalker SW-
200 
Lee’s Summit, MO 
3 days 
 
 
 
 
6078 
 
 
 
 
4031 
 
 
 
 
 
 
 
 
